Sort   by:  
 Page size 
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2025-12-21 | PXD072281 |
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2026-04-19 | PXD077365 |
Analysis of protein interaction between platelets and SARS-CoV-2 envelope protein
ORGANISM(S): Homo Sapiens Severe Acute Respiratory Syndrome Coronavirus 2 
2023-08-08 | PXD037073 |
Sort   by:  
 Page size